



Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/576839
Filing Date	April 20, 2006
First Named Inventor	Alberto
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	1621 WO/US

Sheet 1 of 2

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document Country Code ² Number ² Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		WO 04/097406	11-11-2004	ALBERTO et al.		
		WO 04/022105	03-18-2004	ALBERTO et al.		
		WO 02/087633	11-07-2002	LIU et al.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of The item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ALBERTO et al., Basic Aqueous Chemistry of M(OH)2(CO)3+(M=REM TC) Directed Towards Radiopharmaceutical Application, Coordination Chemistry Reviews, vol. 190-192, 1999, pp. 901-919, XP001074720	
		ALBERTO, Tc(CO)3 chemistry: a promising new concept for SPET, Eur. J. Nucl. Med. Mol. Imaging, vol. 30, September 2003, pp. 1299-1302, XP008051330	
		BELLA et al., A 99mTc(I)-Postlabelled High Affinity Bombesin Analogue as a Potential Tumor Imaging Agent, Bioconjugate Chemistry, American Chemical Society, vol. 13, no. 3, May 15, 2002, pp. 599-604, XP002218739	
		CLARKE, et al., Non-Platinum Chemotherapeutic Metallopharmaceuticals, Chem. Rev. 1999, pp. 2511-2533	
		GELASCO, et al., NMR Solution Structure of a DNA Dodecamer Duplex Containing a cis-Diammineplatinum(II) d(GpG) Intrastrand Cross-Link, the Major Adduct of the Anticancer Drug Cisplatin, Biochemistry, 1998, pp. 9230-9239	
		JAMIESON, et al., Structure, Recognition, and Processing of Cisplatin-DNA Adducts, Chem. Rev. 1999, pp. 2467-2498	
		MUNDWILER, et al., Preparation of No-Carrier-Added Technetium-99m Complexes via Metal-Assisted Cleavage from a Solid Phase, Bioconjugate Chem., vol. 15, December 16, 2003, pp. 195-202, XP008051331	
		MUNDWILER, et al., A new [2+1] mixed ligand concept based on 99mTc(OH)2(CO)3I+ a basic study, Dalton Trans., April 2, 2004, pp. 1320-1328, XP008051349	
		PASINI et al., New Cisplatin Analogues-On the Way to Better Antitumor Agents, Angew. Chem. Int. Ed. Engl., 1987, pp. 615-624	
		PIETZCH et al., Chemical and Biological Characterization of Technetium(I) and Rhenium(I) Tricarbonyl complexes with Dithioether Ligands Serving As Linkers for Coupling the TC(CO)3 and RE(CO)3 Moieties to Biologically Active Molecules, Bioconjugate chemistry, vol. 11, 2000, pp. 414-424, XP001119310	

Examiner Signature	/D. Jones/	Date Considered	12/22/08
--------------------	------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/576839
Filing Date	April 20, 2006
First Named Inventor	Alberto
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	1621 WO/US

Sheet **2** of **2**

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of The item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		SCHIBLI et al., Influence of the Denticity of Ligand Systems on the in vitro and in vivo Behavior of '99I(Tc)-Tricarbonyl Complexes: A Hint for the Future Functionalization of Biomolecules, Bioconjugate Chemistry, vol. 11, no. 3, May 2000, pp. 345-351, XP002218742	
		SPINGLER et al., A Crystal Structure of an Oxaliplatin 1,2-d(GpG) Intrastrand Cross-Link in a DNA Dodecamer Duplex, J. Inorg. Chem., 2001, pp. 5596-5602	
		TAKAHARA et al., Crystal Structure of the Anticancer Drug Cisplatin Bound to Duplex DNA, J. Am. Chem. Soc., 1996, pp. 12309-12321	
		VOLKERT et al., Therapeutic Radiopharmaceuticals, Chem. Rev. 1999, pp. 2269-2292	
		YAN et al., Cytotoxicity of rhenium(I) alkoxo and hydroxo carbonyl complexes in murine and human tumor cells, Pharmazie, 55, 2000, pp. 307-313	
		ZHANG et al., Tricarbonylrhenium(I) complexes of phosphine-derivatized amines, amino acids and a model peptide: structures, solution behavior and cytotoxicity, Journal of Organometallic Chemistry, vol. 650, May 1, 2002, pp. 123-132	
		ZOBI, et al., Toward Novel Binding Metal Complexes: Structure and Basic Kinetic Data of 'M(9MeG)2(CH3PH)(CO)3]+ (MO 99TC, Re), Inorg. Chem., vol. 42, May 4, 2003, pp. 2818-2820, XP008051339	
		ZOBI, et al., Head-to-Head (HH) and Head-to-Tail (HT) Conformers of cis-Bix Guanine Ligands Bound to the [Re(CO)3]+ Core, Inorganic Chemistry, Vol. 43, No. 6, 2004, pp. 2087-2096, XP008051340	

Examiner Signature	/D. Jones/	Date Considered	12/22/08
--------------------	------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. †Applicant's unique citation designation number (optional). ‡See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. §Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ¶For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ¶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ¶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.